MedTrace Logo

Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex

NCT06089252 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-10-18

No results posted yet for this study

Summary

Study aimed to evaluate the efficacy and tolerance of Lazolex®, an emollient gel, to treat mucocutaneous lesions caused by herpes simplex virus.

Conditions

  • HSV Infection

Interventions

DRUG

walnut extract

Four times a day over a 10-day period

Sponsors & Collaborators

  • Iveriapharma LLC

    lead INDUSTRY

Principal Investigators

  • Tina A. Kituashvili, Ph.D, · National Center of Dermatology and Venereology, Tblisi (Georgia)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-27
Primary Completion
2007-12-28
Completion
2008-01-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089252 on ClinicalTrials.gov